Literature DB >> 7681831

Chimeric NK1 (substance P)/NK3 (neurokinin B) receptors. Identification of domains determining the binding specificity of tachykinin agonists.

U Gether1, T E Johansen, T W Schwartz.   

Abstract

The NK1 (substance P) and NK3 (neurokinin B) receptors are G protein-coupled receptors sharing approximately 70% identity within the membrane-spanning domains. However, they each have a distinct pharmacological profile in respect of peptide binding. To identify epitopes that determine their selectivity for natural and synthetic tachykinin peptides, we constructed a series of chimeric NK1/NK3 receptors in which carboxyl-terminal segments of increasing length in the NK1 receptor were exchanged with the corresponding segments from the NK3 receptor. The general, structural integrity of the chimeric constructs was confirmed by the amphibian tachykinin peptide, eledoisin, which was recognized equally well by both of the wild-type receptors and bound with a similar or even higher affinity to all the chimeric receptors. Competition binding studies showed that the affinity of the two natural ligands, substance P and neurokinin B, changed gradually through the series of chimeric receptors indicating that several binding epitopes throughout the receptor structure are involved in the selective recognition of these peptides. However, whereas the single, largest change in binding affinity for substance P occurred when segments in the amino-terminal end of the receptor were exchanged, this occurred for neurokinin B in the carboxyl-terminal end of the receptor. The affinity of the NK1-selective ligand, [Sar9,Met(O2)11]SP, changed even more gradually through the series of chimeric receptors than that of substance P. In contrast, the NK3-selective hexapeptide, senktide, was recognized only when transmembrane segment III and IV from the NK3 receptor were incorporated into the chimeric constructs. These data suggest that several receptor domains contribute to the binding specificity of tachykinin agonists but in varying degrees for each peptide. It is concluded that the tachykinin peptides, in partially different ways, interact with multiple epitopes scattered throughout the receptor structure, but conceivably these epitopes are closely located in space around a hypothetical receptor center.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7681831

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Molecular mapping of epitopes involved in ligand activation of the human receptor for the neuropeptide, VIP, based on hybrids with the human secretin receptor.

Authors:  B Olde; A Sabirsh; C Owman
Journal:  J Mol Neurosci       Date:  1998-10       Impact factor: 3.444

2.  Identification of ligand specificity determinants in AgrC, the Staphylococcus aureus quorum-sensing receptor.

Authors:  Edward Geisinger; Elizabeth A George; John Chen; Tom W Muir; Richard P Novick
Journal:  J Biol Chem       Date:  2008-01-25       Impact factor: 5.157

3.  Molecular Architecture of G Protein-Coupled Receptors.

Authors:  A Michiel van Rhee; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  1996-01-01       Impact factor: 4.360

4.  The CCR5 receptor acts as an alloantigen in CCR5Delta32 homozygous individuals: identification of chemokineand HIV-1-blocking human antibodies.

Authors:  H J Ditzel; M M Rosenkilde; P Garred; M Wang; K Koefoed; C Pedersen; D R Burton; T W Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

5.  Mutational analysis of the interaction of the N- and C-terminal ends of angiotensin II with the rat AT(1A) receptor.

Authors:  C M Costa-Neto; A A Miyakawa; L Oliveira; S A Hjorth; T W Schwartz; A C Paiva
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

6.  CD4-Chemokine receptor hybrids in human immunodeficiency virus type 1 infection.

Authors:  P J Klasse; M M Rosenkilde; N Signoret; A Pelchen-Matthews; T W Schwartz; M Marsh
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

7.  Pharmacological profile of the novel mammalian tachykinin, hemokinin 1.

Authors:  Francesca Bellucci; Francesca Carini; Claudio Catalani; Paola Cucchi; Alessandro Lecci; Stefania Meini; Riccardo Patacchini; Laura Quartara; Renzo Ricci; Manuela Tramontana; Sandro Giuliani; Carlo Alberto Maggi
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

8.  The integrated hypothalamic tachykinin-kisspeptin system as a central coordinator for reproduction.

Authors:  Víctor M Navarro; Martha A Bosch; Silvia León; Serap Simavli; Cadence True; Leonor Pinilla; Rona S Carroll; Stephanie B Seminara; Manuel Tena-Sempere; Oline K Rønnekleiv; Ursula B Kaiser
Journal:  Endocrinology       Date:  2014-11-25       Impact factor: 4.736

9.  Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors.

Authors:  U Gether; Y Yokota; X Emonds-Alt; J C Brelière; J A Lowe; R M Snider; S Nakanishi; T W Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

10.  Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors.

Authors:  H T Schambye; S A Hjorth; D J Bergsma; G Sathe; T W Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.